Inaticabtagene autoleucel
纳基奥仑赛CD19 CAR-T therapy retained in the 2026 Commercial List (#13) with an expanded indication scope adding adult relapsed/refractory LBCL alongside r/r B-ALL.
China Approval (NMPA)
Pending VerificationReimbursement catalog entries for this drug are verified from NHSA official PDFs. Individual NMPA registration certificate numbers (国药准字) and approval dates are queued for incremental verification.
National Reimbursement
Not ListedNot included in the 2025 or 2026 National Reimbursement Drug List (basic medical insurance).
Commercial Insurance List
Announced · Effective Jan 1, 2027- 2026 List Entry
- #13 · 源瑞达
- Validity Period
- 2026-01-01 to 2027-12-31
- MAH / Authorized Entity
- Juventas Cell Therapy Ltd.
- Listed Indication Scope
- Expanded from 2025 (#11, r/r B-ALL only) to cover both adult r/r B-ALL and adult r/r LBCL (DLBCL NOS, transformed FL, PMBCL) after ≥2 lines of systemic therapy.
Catalog inclusion only. Actual reimbursement depends on individual commercial health insurance policy contracts.
Approved Products, Dosage Forms & Approval Numbers
0 verified NMPA recordsChange Timeline
- (2027-01-01)Commercial List· Catalog published: Nov 14, 2026
2026 Commercial List · Indication Expanded (#13)
Expanded from 2025 (#11, r/r B-ALL only) to cover both adult r/r B-ALL and adult r/r LBCL (DLBCL NOS, transformed FL, PMBCL) after ≥2 lines of systemic therapy.
Chinese original: 本品适用于成人复发或难治性B细胞急性淋巴细胞白血病。本品适用于经过二线或以上系统性治疗后成人复发或难治性大B细胞淋巴瘤,包括:弥漫大B细胞淋巴瘤非特指型、滤泡性淋巴瘤转化的大B细胞淋巴瘤、原发性纵隔大B细胞淋巴瘤。
NHSA · PDF p.3Verified 2026-11-20 - (2026-01-01)Commercial List· Catalog published: Dec 7, 2025
2025 Commercial List · Listed (#11)
Adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).
Chinese original: 适用于成人复发或难治性B细胞急性淋巴细胞白血病。
NHSA · PDF p.3Verified 2026-11-20
Verified Names & Aliases
Every English INN, Chinese generic name, brand name, and R&D code is recorded with its source.
Primary Sources for This Record
- NHSAPublished 2026-11-14商业健康保险创新药品目录(2026年)Retrieved 2026-11-20
- NHSAPublished 2025-12-07商业健康保险创新药品目录(2025年)Retrieved 2026-11-20 · 医保发〔2025〕33号附件
- WHO世界卫生组织国际非专利药名(INN)指南Retrieved 2026-11-20